Tag
In a randomized, placebo-controlled phase 1 trial in Uganda, a single intramuscular dose of ChAdOx1 RVF (adenovirus-vectored) was well tolerated and induced rapid T-cell responses and neutralising antibodies, supporting further evaluation o
A phase 4 randomized trial demonstrates that combining rabies monoclonal antibody with vaccine in category 3 exposures is safe, immunogenic, and effective in preventing rabies up to one year post-exposure.
A phase 2 trial in South Africa shows that the M72/AS01E-4 TB vaccine is safe and immunogenic for virally suppressed, ART-treated HIV-positive adolescents and adults, supporting its potential to address a key unmet clinical need.
A new study predicts 11.8 million gastric cancer cases linked to Helicobacter pylori infection among children born 2008-2017, urging stronger global prevention and vaccine development.
MVA-BN vaccination is safe and effective against mpox in at-risk populations, but reduced protection is noted in people living with HIV. Dose strategies and patient immunological status may affect outcomes.
A large US study finds adjuvanted and high-dose quadrivalent influenza vaccines provide comparable protection against lab-confirmed flu in seniors, supporting current immunization guidelines.
A comprehensive Danish cohort study finds no evidence linking early childhood aluminum-adsorbed vaccines to increased risks of autoimmune, allergic, or neurodevelopmental disorders, supporting vaccine safety.
Norovirus vaccines show promise in clinical trials, but scientific and logistical challenges remain. No approved vaccine exists yet, though novel approaches, including oral pills, are advancing development.
Discovery of genetically conserved, mutation-intolerant HIV peptides in rebound virus during analytic treatment interruption highlights new avenues for mRNA vaccine development and functional HIV cure strategies.
